If the merger of Pfizer’s off-patent drug unit and Mylan is approved, Mylan CEO Heather Bresch could earn more than $37.6 million in severance and vested benefits, according to The Pittsburgh Post ...

Pfizer will merge its off-patent drug business with generic drugmaker Mylan, a move that would create a lower-priced medication powerhouse, according to The Wall Street Journal. The combined company ...

Pfizer, the country’s largest drugmaker, is creating a hybrid new drug company by combining its off-patent branded drug business with the generic pharmaceutical company Mylan. Pfizer’s Upjohn, which ...

PITTSBURGH — Mylan has launched a generic drug for fungal infections, the company said Tuesday. Mylan announced the launch, through subsidiary Mylan Pharmaceuticals, of voriconazole tablets in the ...

In separate consent judgments, Pfizer Inc. and Mylan Specialty LP will be required to submit new ad campaigns for EpiPen, a mobile device used to treat acute allergic reactions. Pfizer and Mylan must ...

NEW YORK, March 23 (Reuters) - Mylan Laboratories Inc. said on Friday it launched generic versions of Pfizer Inc.'s blockbuster Norvasc blood-pressure drug, a day after a federal court ruled a Pfizer ...

If you use an EpiPen, you might be able to get $90 from a class-action lawsuit.

Viatris has agreed to a settlement in which it will pay up to $335 million to resolve opioid-related claims to state and local governments, the Pittsburgh-based generics specialist said on Monday.

The proposed settlement, which requires a judge’s approval, would resolve a legal battle that began after the company, in 2016, raised the price for two EpiPens to $608 from $100. By Jesus Jiménez The ...

Beginning in 2020, Upjohn began managing Pfizer’s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and a pre-existing strategic collaboration between Pfizer and Mylan ...